RxDoctor Payments DataLook up a doctor →

Rajesh Kumar, MD

Psychiatry · West Bend, WINPI 1194800557

Payments from drug & device makers

$22,650in general payments, 2019–2025

Across 1,170 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Lundbeck LLC$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • AbbVie$2K
  • Alkermes, Inc.$2K
  • Axsome Therapeutics, Inc.$1K
  • plus $11K from 31 others

What the payments were for

  • Food & beverage$22,03397%
  • Education$6163%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,650 in reported general payments places this provider in the 95th percentile of 543 psychiatry providers in Wisconsin.

See all psychiatry providers in Wisconsin

Medicare billing

Part B allowed, 2024
$124,255
Medicare patients
86
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl56$129,562
AustedoDeutetrabenazine15$71,994
Austedo XrDeutetrabenazine12$49,410
TrintellixVortioxetine Hydrobromide44$36,757
FanaptIloperidone11$35,592
Effexor XrVenlafaxine Hcl12$20,024
Invega SustennaPaliperidone Palmitate13$14,071
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$8,043
FetzimaLevomilnacipran Hcl11$6,291
Mirtazapine221$3,785
Fluphenazine Hcl28$3,561
Duloxetine Hcl122$2,873
Lisdexamfetamine Dimesylate12$2,583
Vilazodone Hcl15$2,541
Asenapine Maleate14$2,290

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Invega Sustenna$2,424$143,63469 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$675$121,40427 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$768$36,75744 claims
Vanda Pharmaceuticals Inc.Fanapt$744$35,59211 claims
Orexo US, Inc.Zubsolv$277$8,04313 claims
AbbVieFetzima$1,932$6,29111 claims
Almatica Pharma LLCSertraline Hcl$272$46165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 543 psychiatry providers in Wisconsin.

Other psychiatry in West Bend

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →